IRF2 and neoplasm: miR-302b suppresses tumor growth and transcription factors protein expression through targeting erb-b2 receptor tyrosine kinase 4 (ERBB4), interferon regulatory factor 2 (IRF2), and Cxc chemokin receptor 4 (CXCR4) in esophageal cancer (19).